CMS: Doctors, hospitals received $8.4B in payments from drug companies last year

CMS' released its latest Open Payments database last week. (Getty/Utah778)

Doctors and teaching hospitals received $8.4 billion in payments from drug companies in 2017, according to the latest Open Payments data released by the Centers for Medicare & Medicaid Services.

Under the Sunshine Act, CMS is required to publish financial interactions between manufacturers of drugs, devices, biologicals and medical supplies and individual physicians and teaching hospitals.

The 2017 payments included nearly $4.7 billion in research related payments, $2.82 billion in non-research-related payments and more than $927 million representing ownership or investment interests held by physicians or their immediate family members, according to CMS data.

Free Daily Newsletter

Like this story? Subscribe to FierceHealthcare!

The healthcare sector remains in flux as policy, regulation, technology and trends shape the market. FierceHealthcare subscribers rely on our suite of newsletters as their must-read source for the latest news, analysis and data impacting their world. Sign up today to get healthcare news and updates delivered to your inbox and read on the go.

RELATED: No free lunch? Study finds meals from pharma linked to uptick in opioid prescriptions

According to the latest data, 628,000 physicians received $79.1 million in research-related payments and nearly $2.1 billion in general payments in 2017.

More than 1,100 teaching hospitals received payments from drug companies including $1 billion in research payments and $751.2 million in non-research payments. 

Of course, the release of the data has raised the ire of physicians groups who have questioned the quality of the data released as well as lack of context around what the payments mean. Indeed, 258 of the research-related payments and 758 of the non-research-related payments have been disputed.

Suggested Articles

Humana filed suit Friday against more than a dozen generic drugmakers alleging the companies engaged in price fixing.

Ochsner Health System is partnering with Color to launch a population health pilot program to integrate genetic information into preventive care.

Medicare Advantage open enrollment kicked off last week, and insurers are taking new approaches to marketing a slate of supplemental benefit options.